Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 9/20 | 0.67 |
| ▸ | ACE | P12821 | 11/20 | 0.63 |
| ▸ | CPA1 | P15085 | 4/20 | 0.59 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.59 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25627017 | 0.99 | MME (0.66) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL22457647 | 0.93 | MME (0.67) | MMEACECPA1ACE2 | |
| Hydrochloric Acid SCHEMBL29670155 | 0.91 | MME (0.65) | MMEACECPA1ACE2 | |
| SCHEMBL25627310 | 0.91 | MME (0.60) | MMEACECPA1ACE2FOLH1 | |
| SCHEMBL30091378 | 0.88 | MME (0.72) | MMEACECPA1ACE2 | |
| SCHEMBL23306955 | 0.88 | MME (0.53) | MMEACECPA1ACE2 | |
| SCHEMBL22880674 | 0.88 | TSHR (0.68) | MME | |
| SCHEMBL15692299 | 0.87 | MME (0.66) | MMEACECPA1ACE2 | |
| SCHEMBL5997104 | 0.87 | MME (0.66) | MMEACECPA1ACE2 | |
| SCHEMBL31073975 | 0.87 | MME (0.62) | MMEACECPA1ACE2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2025-12-02 | — | — | US | disclosed |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | CDRD VENTURES INC. (CA) | 2022-04-14 | — | — | US | disclosed |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | CDRD VENTURES INC. (CA) | 2022-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12486302-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | MME 741/4885ACE 839/4885CPA1 338/4885 |
| US-11279732-B2 | Somatostatin receptor antagonist compounds and methods of using the same | GPR119, SSTR5, SSTR2 | MME 776/4885ACE 836/4885CPA1 303/4885 |
| US-20220112242-A1 | SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME | GPR119, SSTR5, SSTR2 | MME 741/4885ACE 839/4885CPA1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.